Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
KinDex Pharmaceuticals, Inc. See All Filings	D	2019-05-13 17:41:50 UTC
Amount To Be Raised $2,000,000 Associated Brokers / Dealers N/A CIK Number 0001602462 Filed Document 0001602462-19-000001 Exclusions or Exemptions 506b Accepted Date 2019-05-13 17:41:50 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
KinDex Pharmaceuticals, Inc. See All Filings	D/A	2017-06-27 13:13:56 UTC
Amount To Be Raised $1,300,001 Associated Brokers / Dealers N/A CIK Number 0001602462 Filed Document 0001602462-17-000001 Exclusions or Exemptions 506b Accepted Date 2017-06-27 13:13:56 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business WASHINGTON Revenue or Assets Decline to Disclose Type of Security Debt
KinDex Pharmaceuticals, Inc. See All Filings	D	2016-08-30 13:10:42 UTC
Amount To Be Raised $600,001 Associated Brokers / Dealers N/A CIK Number 0001602462 Filed Document 0001602462-16-000002 Exclusions or Exemptions 506b Accepted Date 2016-08-30 13:10:42 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business WASHINGTON Revenue or Assets Decline to Disclose Type of Security Debt
KinDex Pharmaceuticals, Inc. See All Filings	D/A	2015-03-06 00:00:00 UTC
Amount To Be Raised $10,000,000 Associated Brokers / Dealers N/A CIK Number 0001602462 Filed Document 0001602462-15-000001 Exclusions or Exemptions 506b Accepted Date 2015-03-06 00:00:00 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business WASHINGTON Revenue or Assets Decline to Disclose Type of Security Equity
KinDex Pharmaceuticals, Inc. See All Filings	D	2014-03-12 00:00:00 UTC
Amount To Be Raised $10,000,000 Associated Brokers / Dealers N/A CIK Number 0001602462 Filed Document 0001602462-14-000001 Exclusions or Exemptions 506b Accepted Date 2014-03-12 00:00:00 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business WASHINGTON Revenue or Assets Decline to Disclose Type of Security Equity